lowRISC Collaborates with Industry Leaders to Create OpenTitan
5.11.2019 17:00:00 EET | Business Wire | Press release
lowRISC C.I.C., the open source silicon and tools collaborative engineering company, today announced that it has partnered with ETH Zürich, Google, G+D Mobile Security, Nuvoton Technology and Western Digital in support of OpenTitan, an open source hardware root of trust (RoT) reference design and integration guidelines that enable chip producers and platform providers to build transparently implemented, high-quality hardware RoT chips tailored for data center servers and other devices.
Security begins with infrastructure, and OpenTitan will help ensure root of trust in hardware, transparently implemented, at the foundation for a multitude of devices such as server motherboards, network cards, routers and IoT. Adopters of this framework can inspect and contribute to OpenTitan’s register-transfer level (RTL) design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips for everyone.
OpenTitan is stewarded by lowRISC, which provides a neutral home for collaborative engineering to develop and maintain open source silicon designs and tools for the long term. As with open source software, open silicon provides a deep level of transparency and therefore auditability, as well as enabling innovation. Shared open infrastructure technology permits focus on product differentiation, with shared costs and substantially reduced overall risk.
The Ibex RISC-V processor core, which was originally developed by ETH Zürich as zero-riscy and contributed to lowRISC earlier this year, forms a key component for OpenTitan. lowRISC is committed to raising the bar for quality in open silicon via a methodical approach that combines the development and use of best practices and coding standards, with rigorous testing and verification.
Key benefits of OpenTitan for chip manufacturers and platform providers include:
- Transparent: Adopters can inspect and contribute to OpenTitan’s design, firmware, and documentation, helping to build more transparent, trustworthy hardware RoT chips that benefit everyone.
- High-quality: OpenTitan’s goal is to build and maintain a high-quality and logically secure RTL design, firmware, and documentation. The project is staffed by expert engineers focused on rigorous design validation and technical documentation, all based on key learnings from designing Google’s Titan chips.
- Flexible: Adopters can increase their total addressable market and reduce costs by using a single platform-agnostic hardware RoT design that can be integrated in data center servers, peripherals, and any other hardware platforms.
“We believe collaboratively developed open source silicon designs provide the flexible, cost effective base needed for future generations of secure hardware products,” said Alex Bradbury, lowRISC CTO. “The lowRISC not-for-profit structure combined with full stack engineering capabilities in-house, enables us to manage high quality projects like OpenTitan, and we look forward to developing this partnership and new ones in the future.”
“At lowRISC, our mission is to establish a vibrant ecosystem around open silicon designs and to help lower the barrier to producing custom chips,” said Gavin Ferris, lowRISC CIC board member. “Creating an ecosystem of like-minded organizations focused on the goal of improving transparency around chips helps increase trust in the overall security of the infrastructure on which software runs. With OpenTitan, enterprise organizations and consumers alike will benefit from services built on a more secure infrastructure that is anchored in transparently implemented OpenTitan chips.”
“Customers are asked to put faith in proprietary hardware RoT chips for their mission-critical systems without the ability to fully understand, inspect and therefore trust them,” said Dominic Rizzo, OpenTitan Lead at Google and lowRISC’s OpenTitan Project Director. “By creating OpenTitan with the broader hardware and academic community, we can leverage the experience and security principles used to create Google’s own Titan chips to make hardware RoT designs more transparent, inspectable, and accessible to the rest of the industry. Security should never be built on opacity.”
Collaboration is fundamental to open silicon and at the core of everything that lowRISC does, bringing to projects a deep understanding of open source licensing, contributor models and community building, and providing a uniquely positioned engineering capability.
About lowRISC
lowRISC C.I.C. is a not-for-profit company that aims to demonstrate, promote and support the use of open-source hardware - bringing the benefits of open-source to the hardware world. We are producing high-quality, security-focused, open, and flexible IP. Our expertise includes the LLVM Compiler, novel hardware security extensions and RISC-V tools, hardware and processor design.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005089/en/
Contact information
Andrew Back
lowRISC
press@lowrisc.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release
Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
